期刊
BLOOD
卷 123, 期 24, 页码 3790-3796出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-12-543306
关键词
-
类别
资金
- Spanish Ministry of Economy and Competitiveness through the Instituto de Salud Carlos III (ISCIII) (International Cancer Genome Consortium-Chronic Lymphocytic Leukemia Genome Project)
- Red Tematica de Investigacion del Cancer of the ISCIII [RD12/0036/0036, RD12/0036/0023, RD12/0036/0004, RD12/0036/0069, PIE13/00033, RD12/0036/0067]
- Plan Nacional [SAF12/38432]
- Generalitat de Catalunya [2009-SGR-992]
Mutations in Toll-like receptor (TLR) and myeloid differentiation primary response 88 (MYD88) genes have been found in chronic lymphocytic leukemia (CLL) at low frequency. We analyzed the incidence, clinicobiological characteristics, and outcome of patients with TLR/MYD88 mutations in 587 CLL patients. Twenty-three patients (3.9%) had mutations, 19 in MYD88 (one with concurrent IRAK1 mutation), 2 TLR2 (one with concomitant TLR6 mutation), 1 IRAK1, and 1 TLR5. No mutations were found in IRAK2 and IRAK4. TLR/MYD88-mutated CLL overexpressed genes of the nuclear factor kappa B pathway. Patients with TLR/MYD88 mutations were significantly younger (83% age <= 50 years) than those with no mutations. TLR/MYD88 mutations were the most frequent in young patients. Patients with mutated TLR/MYD88 CLL had a higher frequency of mutated IGHV and low expression of CD38 and ZAP-70. Overall survival (OS) was better in TLR/MYD88-mutated than unmutated patients in the whole series (10-year OS, 100% vs 62%; P = .002), and in the subset of patients age <= 50 years (100% vs 70%; P = .02). In addition, relative OS of TLR/MYD88-mutated patients was similar to that in the age-and gender-matched population. In summary, TLR/MYD88 mutations identify a population of young CLL patients with favorable outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据